Large Molecule Bioanalysis
Advance Your Therapy With Our Dedicated Team
Work with a team of experts at the forefront of analytical testing for the next generation of biotherapeutics. WuXi Biology and Testing offers comprehensive capabilities and a sophisticated technology platform dedicated to clearing a path to more efficiently advance your biotherapies to market.
Industry-Leading Bioanalysis for Large Molecules
Our bioanalytical team has the experience and expertise to help you move your drug candidate to the next milestone. We’ll customize a program that meets your project’s evolving needs and supports you from preclinical through new drug application (NDA).
- Pharmacokinetics (PK) Bioanalytical Services
- Toxicokinetics (TK) Bioanalytical Services
- Immunogenicity ADA and Neutralizing Antibody (NAb) Service
- Statistical analysis of Cut-Point and Low Positive Control determination
- Exploratory and decision-making biomarker screening/discovery: Ligand Binding Assay (LBA) and LC-MS/MS Services
- Monoclonal and Polyclonal Reagent Generation
Our Large Molecule Bioanalytical Experience
We are experts at delivering advanced bioanalytical programs customized to a specific biotherapy. Our team has years of experience executing validated assays across a range of testing platforms.
Explore Our Large Molecule Bioanalysis Services
Your ability to make intelligent, informed decisions hinges on having the right bioanalytical strategy. We can help you develop an approach that will take you from discovery through preclinical to IND and beyond – with leading efficiency and speed.
Immunogenicity Bioanalytical Services (GLP)
Biological drugs pose unique challenges during development, particularly their higher likelihood of triggering an immune response compared to small molecule drugs, which can result in adverse effects. Regulatory agencies mandate comprehensive immunogenicity testing, and paying attention to this critical component in your IND package can help prevent significant clinical delays. We partner with our clients to develop tailored reagents and assays that assess and predict key immune response markers. Our expert team also provides comprehensive support in implementing multi-tiered testing strategies that comply with the latest regulatory immunogenicity guidelines.
Screening Confirmatory & Titer Determination
We’re experts in the screening, confirmatory, and titer determination processes for biological therapeutics. We provide advanced assays, statistical analysis, and precise results, ensuring high drug tolerance and compliance with U.S. regulatory agency standards.
- Reagent generation to fit biological therapeutic using monoclonal or polyclonal antibodies for positive controls and epitope-specific reagent purification
- Anti-drug antibody (ADA) electrochemiluminescent (ECL) bridging assays with capabilities of executing complex assays for difficult biotherapeutics
- Statistical analysis of cut-point and low positive controls in report format acceptable to U.S. regulatory agencies
- Non-cell-based neutralizing antibody (NAb) assays
- High drug tolerance with bead extraction and acid dissociation (BEAD)
- Cell-based neutralizing antibody assays
Regulatory Support
Get broad and deep regulatory guidance and support throughout every stage of your development process.
- GLP/non-GLP bioanalytical facilities
- Central laboratory services – safety lab and clinical kits
- Support for innovator and biosimilar drugs
- Clinical and preclinical study support
- Submitted data accepted by worldwide health authorities
- Completed U.S. regulatory agency, EMA, PMDA, NMPA (CFDA) study inspections with minor observations and no deficiencies
- Completed multiple GLP inspections and certifications by OECD
- Successfully complete 50+ client inspections each year
- Drug Enforcement Agency-inspected, state licensed for radioactivity use (U.S.)
Explore More in Large Molecule Bioanalysis
Discovery and Non-GLP Bioanalysis
Expert non-GLP bioanalytical solutions to accelerate drug discovery.
Preclinical Bioanalysis (GLP)
Preclinical bioanalytical support for successful IND submission.
Explore Solutions for Your Program
Explore solutions by development phase, drug modality, therapeutic area, or integrated discovery needs.
Get a Quote
Ready to plan your next study? Share your program needs with our team for a tailored estimate.
Large Molecule Bioanalytical FAQ
Quantitative analysis of large molecules involves measuring biological drugs, including proteins, peptides, and monoclonal antibodies, in different biological samples. This method is crucial for assessing the pharmacokinetics, effectiveness and safety of large molecule treatments.
Testing large molecules through bioanalysis is crucial because of their intricate structures and distinctive pharmacokinetic characteristics. Precise measurement is essential for scientists to understand their absorption, distribution, metabolism, and excretion, which is vital for optimizing dosage and conducting safety assessments.
Large molecule samples usually consist of blood, plasma, serum, urine, tissue and other biological fluids. They are examined to measure the levels of medications and their byproducts.
Commonly employed techniques for large molecule bioanalysis include ligand-binding assays (LBAs) like enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence (ECL) and surface plasmon resonance (SPR). In addition, mass spectrometry-based methods (e.g., LC-MS/MS) are utilized for comprehensive analysis.
Bioanalytical techniques for large molecules undergo validation in compliance with regulatory standards to guarantee accuracy, precision, sensitivity, specificity and reproducibility. Validation serves to verify that the techniques yield dependable and uniform results.
Bioanalysis of large molecules must adhere to regulatory guidelines set forth by international regulatory bodies. These guidelines delineate the criteria for validating methods, analyzing samples, and reporting data.
Yes, bioanalytical services can be customized to cater to the specific requirements of various large molecule projects. This encompasses developing and validating distinctive analytical methods to tackle particular research inquiries.
Challenges arise from large molecules’ intricate structure and size, their potential immunogenicity, and the requirement for highly sensitive and specific analytical methods. Overcoming these challenges is made possible with advanced techniques and the expertise of experienced scientists.
The timeframe for a large molecule bioanalysis study is contingent upon the project's complexity, the quantity of samples, and the analytical methods needed. Typically, timelines are deliberated and finalized during the project planning phase.
We offer a range of large molecule bioanalytical services, including pharmacokinetics (PK), toxicokinetics (TK), immunogenicity testing, and biomarker discovery. These services support drug development from discovery to regulatory submissions, including extensive experience with new modalities.
The lab utilizes advanced technologies such as Ligand Binding Assays (LBA), LC-MS/MS, and cell-based assays to ensure precise and reliable results.
Yes, we tailor our bioanalytical programs to meet the evolving needs of each project, ensuring efficient and practical advancement of drug candidates.
We provide comprehensive immunogenicity testing, including anti-drug antibody (ADA) and neutralizing antibody (NAb) assays, adhering to U.S. regulatory guidelines.
We support all stages of regulatory submission, providing expert guidance and customized testing to meet stringent regulatory standards.
We have leading integrated laboratory operations in New Jersey and China, including Central Laboratory Services.



